CHARGED ALPHA
Stock Analysis
Stock Library / PXED
PXED Unclassified Latest YouTube: Q3 FY2026

PXED

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

PXED Stock: University of Phoenix Trades at 7x Earnings — and Fears One Number

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q3 FY2026
Podcast available
Yes
Current price
$30.16
-0.30 (-0.98%)
Trailing / Forward P/E
13.83x
Forward: 6.43x
Market cap / Volume
Volume:
Revenue / Earnings Growth
0.0%
Earnings: -28.9%
Margins
21.0% op
Gross: 56.5% · Net: 8.2%
Balance sheet
1.92x current
Debt / Equity: 20.1
52-week range / Beta
$23.52 - $47.08
Beta: —
Analyst target
$42.75
Upside: 41.7%
Cash / shareholder return
16.08% FCF yield
Dividend yield: 2.07%

Company context

Industry: Education & Training Services
Country: United States
Employees:
Price to book: 3.71x
Return on equity: 25.3%
Phoenix Education Partners, Inc., through its subsidiary, The University of Phoenix, Inc., provides online higher education for working adults in the United States. It develops talent solutions programs for employers, including a talent-sourcing platform that connects employers with students whose skills profiles align with job postings; and an AI-powered tool that scans an employer's inventory of sought-after skills and designs development pathways to internal job opportunities. The company was formerly known as AP VIII Queso Holdings, L.P. and changed its name to Phoenix Education Partners, Inc. in September 2025. The company was founded in 1976 and is headquartered in Phoenix, Arizona. Phoenix Education Partners, Inc. operates as a subsidiary of Ap Viii Socrates Holdings, L.P.

Price chart

Market context for PXED

Competitive view

PXED vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

PXED latest YouTube video thumbnail YouTube
PXED
PXED
Latest video
Q3 FY2026
Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Abbott Laboratories latest YouTube video thumbnail YouTube
Abbott Laboratories
ABT
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
PXED
$1.09B
PXED
ADBE
$94.31B
ADBE
ABT
$175.37B
Abbott Laboratories
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
PXED
13.8x
PXED
ADBE
13.6x
ADBE
ABT
28.2x
Abbott Laboratories
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
PXED
6.4x
PXED
ADBE
8.6x
ADBE
ABT
16.6x
Abbott Laboratories
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
PXED
0.0%
PXED
ADBE
12.7%
ADBE
ABT
7.8%
Abbott Laboratories
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
PXED
-28.9%
PXED
ADBE
7.9%
ADBE
ABT
-19.7%
Abbott Laboratories
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
PXED
21.0%
PXED
ADBE
35.3%
ADBE
ABT
13.5%
Abbott Laboratories
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
PXED
56.5%
PXED
ADBE
89.4%
ADBE
ABT
56.5%
Abbott Laboratories
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
PXED
8.2%
PXED
ADBE
28.7%
ADBE
ABT
13.9%
Abbott Laboratories
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
PXED
25.3%
PXED
ADBE
63.0%
ADBE
ABT
12.3%
Abbott Laboratories
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
PXED
16.1%
PXED
ADBE
9.8%
ADBE
ABT
3.6%
Abbott Laboratories
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
PXED
20.13x
PXED
ADBE
61.44x
ADBE
ABT
64.77x
Abbott Laboratories
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
PXED
1.92x
PXED
ADBE
0.75x
ADBE
ABT
1.39x
Abbott Laboratories
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
PXED
PXED
ADBE
1.43
ADBE
ABT
0.61
Abbott Laboratories
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
PXED
2.1%
PXED
ADBE
ADBE
ABT
2.8%
Abbott Laboratories
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
PXED
41.7%
PXED
ADBE
14.8%
ADBE
ABT
15.8%
Abbott Laboratories

Related research

Non-quarter videos featuring PXED

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-15

University of Phoenix at 7x earnings — and terrified of one number. #PXED #stocks #investing

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for PXED

Each row is one earnings episode with every verified platform link available.

Q3 FY2026
Episode live
Published youtube podcast complete
PXED Stock: University of Phoenix Trades at 7x Earnings — and Fears One Number
Quarterly earnings-analysis entry for PXED. Use the links on the right to open the video or podcast episode.